Advion invests more in LIMS
14 April 2008Tweet
Thermo Fisher Scientific is expanding its partnership with Advion BioServices the bioanalytical services division of Advion BioScience.
Adivon has increased its investment in Thermo Scientific Watson LIMS to enhance its bioanalytical capabilities and satisfy the company’s expansion goals.
Thermo Scientific Watson LIMS is specifically designed to support drug metabolism and pharmacokinetic (DMPK) studies in drug discovery and development, and is installed in 18 of the top 20 global pharmaceutical organisations and leading CROs around the world.
‘The additional investment in Thermo Scientific Watson LIMS is essential to Advion’s ability to meet the ever increasing needs of our sponsor organisations and will help Advion keep pace with market requirements,’ said David Hardwick, Advion’s director of laboratory operations. ‘Our long-term partnership with Thermo Fisher Scientific has made a meaningful impact on our operations by providing software solutions to address our data management needs. Our use of the Watson LIMS system has been instrumental in our success as a provider of world-class bioanalytical services.’
For bioanalytical laboratories and CROs, Watson LIMS is designed to support drug metabolism and pharmacokinetic (DMPK) studies in drug discovery and development; Galileo LIMS enables high-throughput compound screening for in vitro ADME studies; Nautilus LIMS is designed for flexible environments preferred by research organiSations; Darwin LIMS was developed specifically for pharmaceutical manufacturing R&D and QA/AC.